Treating inflammatory skin disorders by blocking a molecular pathway
This article was originally published in Start Up
Nearly a decade ago, scientists began publishing studies that aroused excitement in the generally sleepy, low-innovation market for dermatology products. The finding that nerve growth factor is involved in inflammatory and autocrine diseases like psoriasis has since spurred many attempts to develop new treatments for underserved mild to moderate skin disorders. Several companies have taken into clinical-phase testing drug candidates that target different points along NGF’s pathway. For its part, Creabilis SA is developing a new chemical entity it believes can treat both psoriasis and atopic dermatitis by blocking NGF’s high affinity receptor, TrkA, with a kinase inhibitor presently known as CT327.
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.